Estrella Immunopharma (ESLA) Competitors $0.92 +0.07 (+8.23%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ESLA vs. RPTX, CNTX, IPHA, PLX, MCRB, ANRO, AVTX, IFRX, CABA, and VXRTShould you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Repare Therapeutics (RPTX), Context Therapeutics (CNTX), Innate Pharma (IPHA), Protalix BioTherapeutics (PLX), Seres Therapeutics (MCRB), Alto Neuroscience (ANRO), Avalo Therapeutics (AVTX), InflaRx (IFRX), Cabaletta Bio (CABA), and Vaxart (VXRT). These companies are all part of the "pharmaceutical products" industry. Estrella Immunopharma vs. Repare Therapeutics Context Therapeutics Innate Pharma Protalix BioTherapeutics Seres Therapeutics Alto Neuroscience Avalo Therapeutics InflaRx Cabaletta Bio Vaxart Estrella Immunopharma (NASDAQ:ESLA) and Repare Therapeutics (NASDAQ:RPTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, valuation and community ranking. Which has stronger earnings & valuation, ESLA or RPTX? Estrella Immunopharma has higher earnings, but lower revenue than Repare Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEstrella ImmunopharmaN/AN/A-$7.31M-$0.26-3.54Repare Therapeutics$51.13M2.36-$93.80M-$2.00-1.42 Do analysts prefer ESLA or RPTX? Repare Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 252.11%. Given Repare Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Repare Therapeutics is more favorable than Estrella Immunopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Estrella Immunopharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Repare Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media prefer ESLA or RPTX? In the previous week, Estrella Immunopharma had 1 more articles in the media than Repare Therapeutics. MarketBeat recorded 1 mentions for Estrella Immunopharma and 0 mentions for Repare Therapeutics. Estrella Immunopharma's average media sentiment score of 0.00 beat Repare Therapeutics' score of -0.20 indicating that Estrella Immunopharma is being referred to more favorably in the media. Company Overall Sentiment Estrella Immunopharma Neutral Repare Therapeutics Neutral Which has more volatility and risk, ESLA or RPTX? Estrella Immunopharma has a beta of 0.24, meaning that its share price is 76% less volatile than the S&P 500. Comparatively, Repare Therapeutics has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Does the MarketBeat Community prefer ESLA or RPTX? Repare Therapeutics received 41 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. CompanyUnderperformOutperformEstrella ImmunopharmaN/AN/ARepare TherapeuticsOutperform Votes4165.08% Underperform Votes2234.92% Is ESLA or RPTX more profitable? Estrella Immunopharma has a net margin of 0.00% compared to Repare Therapeutics' net margin of -99.76%. Repare Therapeutics' return on equity of -40.87% beat Estrella Immunopharma's return on equity.Company Net Margins Return on Equity Return on Assets Estrella ImmunopharmaN/A -195.77% -157.28% Repare Therapeutics -99.76%-40.87%-35.07% Do institutionals and insiders believe in ESLA or RPTX? 0.4% of Estrella Immunopharma shares are held by institutional investors. Comparatively, 85.1% of Repare Therapeutics shares are held by institutional investors. 55.1% of Estrella Immunopharma shares are held by insiders. Comparatively, 21.6% of Repare Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryRepare Therapeutics beats Estrella Immunopharma on 11 of the 17 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Estrella Immunopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ESLA vs. The Competition Export to ExcelMetricEstrella ImmunopharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.79M$2.94B$5.05B$8.87BDividend YieldN/A1.89%4.97%4.06%P/E Ratio-3.5421.3797.3414.18Price / SalesN/A382.101,218.4289.42Price / CashN/A160.1133.5132.79Price / Book46.034.195.805.12Net Income-$7.31M-$41.63M$119.07M$225.99M7 Day Performance9.58%-4.73%-1.83%-1.32%1 Month Performance10.64%-6.53%-3.64%0.60%1 Year Performance-34.25%25.63%31.62%26.23% Estrella Immunopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ESLAEstrella Immunopharma0.6276 of 5 stars$0.92+8.2%N/A-33.5%$30.79MN/A-3.54N/AHigh Trading VolumeRPTXRepare Therapeutics2.672 of 5 stars$2.84-1.4%$10.00+252.1%-44.7%$122.43M$51.13M0.00180CNTXContext Therapeutics2.0666 of 5 stars$1.63-1.2%$6.25+283.4%+81.1%$122.25MN/A-1.817IPHAInnate Pharma2.2362 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$120.64M$66.71M0.00220News CoverageGap UpPLXProtalix BioTherapeuticsN/A$1.69+3.7%N/A+22.0%$120.02M$65.49M0.00200Analyst UpgradeHigh Trading VolumeMCRBSeres Therapeutics3.8903 of 5 stars$0.81+19.0%$5.08+524.6%-16.1%$117.54M$126.32M0.00233Analyst UpgradeHigh Trading VolumeANROAlto Neuroscience3.532 of 5 stars$4.27-4.7%$20.00+368.4%N/A$115.16M$210,000.000.00N/AAnalyst RevisionAVTXAvalo Therapeutics2.3623 of 5 stars$10.90-1.4%N/A-47.4%$113.30M$820,000.000.0040Positive NewsIFRXInflaRx3.0872 of 5 stars$2.04+6.3%$8.00+292.2%+34.2%$113.06M$70,000.000.0060Gap UpCABACabaletta Bio2.0246 of 5 stars$2.26-11.0%$27.30+1,108.0%-87.4%$110.47MN/A-1.0550Analyst ForecastHigh Trading VolumeVXRTVaxart2.1331 of 5 stars$0.61-1.6%$3.00+393.6%-22.1%$110M$7.38M0.00109Analyst RevisionNews Coverage Related Companies and Tools Related Companies Repare Therapeutics Competitors Context Therapeutics Competitors Innate Pharma Competitors Protalix BioTherapeutics Competitors Seres Therapeutics Competitors Alto Neuroscience Competitors Avalo Therapeutics Competitors InflaRx Competitors Cabaletta Bio Competitors Vaxart Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ESLA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
